Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients - Scorecard - MDSpire

Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients

  • By

  • Katharina Hartman

  • Guido Steiner

  • Cary M. Looney

  • Michel Siegel

  • Katharine Bray-French

  • Klaudia Brix

  • Sebastian Springer

  • Timothy P. Hickling

  • Niels Janssen

  • Axel Ducret

  • Céline Marban-Doran

  • July 7, 2026

Share

Clinical Scorecard: Personalized Healthcare-Driven Assays for Direct Identification of Potential T Cell Epitopes in Patients Using Clinical MAPPs

At a Glance

CategoryDetail
ConditionImmunogenicity of Therapeutic Monoclonal Antibodies
Key MechanismsPresentation of mAb-derived peptides by dendritic cells activating CD4+ T-helper cells.
Target PopulationPatients undergoing treatment with therapeutic monoclonal antibodies.
Care SettingClinical trials and personalized healthcare settings.

Key Highlights

  • Introduction of Clinical MAPPs for personalized immunogenicity risk assessment.
  • Utilizes low volume blood samples (10 mL) for analysis.
  • Enables identification of MHC-II receptor-associated antibody-derived peptides.
  • Facilitates monitoring of anti-drug antibody (ADA) onset in patients.
  • Compares peptide presentation profiles between moDCs and naturally occurring DCs.

Guideline-Based Recommendations

Diagnosis

  • Utilize Clinical MAPPs to identify potential immunogenicity risks before mAb treatment.

Management

  • Implement personalized treatment plans based on ADA monitoring results.

Monitoring & Follow-up

  • Assess ADA onset before and after mAb treatment using Clinical MAPPs.

Risks

  • Consider the multifactorial causes of immunogenicity, including treatment modality and patient factors.

Patient & Prescribing Data

Patients enrolled in clinical trials receiving therapeutic monoclonal antibodies.

Clinical MAPPs allows for tailored immunogenicity assessments to enhance treatment safety and efficacy.

Clinical Best Practices

  • Employ Clinical MAPPs for early prediction of immunogenicity risks.
  • Use cryopreserved PBMCs for assay compatibility and robustness.
  • Monitor patient-specific immune responses to optimize therapeutic outcomes.

Related Resources & Content

    Original Source(s)

    Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients

    • by Katharina Hartman, Guido Steiner, Cary M. Looney, Michel Siegel, Katharine Bray-French, Klaudia Brix, Sebastian Springer, Timothy P. Hickling, Niels Janssen, Axel Ducret, Céline Marban-Doran

    • July 7, 2026

    Related Content

    The Journey of a Sample

    Rethinking sustainability in the complex world of clinical trials

    Side Effects: Bro Science, Actually

    Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

    The Pick fold in tau filaments from human MAPT mutants